Back to top
more

Aurinia Pharmaceuticals (AUPH)

(Delayed Data from NSDQ)

$5.03 USD

5.03
785,988

-0.06 (-1.18%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $5.03 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock

by Zacks Equity Research

Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.

Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?

by Zacks Equity Research

Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.

AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL

by Zacks Equity Research

Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio

Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag

by Zacks Equity Research

The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.

Is it a Good Idea to Invest in KalVista (KALV) Stock Now?

by Zacks Equity Research

Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.

Here's Why You Should Invest in Alpine (ALPN) Stock Now

by Zacks Equity Research

Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.

Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics

by Zacks Equity Research

Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Stocks to Buy as Drug Industry Displays Strong Fundamentals

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.

Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs

by Zacks Equity Research

Avalo (AVTX) will receive an upfront payment of $150,000 on selling three compounds to AUG Therapeutics. The company is also eligible to receive milestone payments of up to $45 million.

Wall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 42.9% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aurinia Pharmaceuticals (AUPH) and Bausch Health (BHC) have performed compared to their sector so far this year.

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 60% and 14.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

KalVista (KALV) Surges 15% on Update From Angioedema Study

by Zacks Equity Research

KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angioedema attacks. The stock rises 15% in response.

Aurinia (AUPH) Up on Paving the Way for a Potential Buyout

by Zacks Equity Research

Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.

Aurinia (AUPH) Moves 5.7% Higher: Will This Strength Last?

by Zacks Equity Research

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Aurinia Pharmaceuticals (AUPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 25% and 24.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 11.11% and 7.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent

by Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.

Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 30.77% and 0.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates

by Ekta Bagri

We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.